



DRUG TESTING PROGRAM



1. DRUG-FREE COMPETITION

As the world's definitive test of fitness, CrossFit Games competitions stand not only as testaments to the athletes who compete but to the training methodologies they use. In this arena, a true and honest comparison of training practices and athletic capacity is impossible without a level playing field. Therefore, the use of banned performance-enhancing substances is prohibited. Even the legal use of banned substances, such as physician-prescribed hormone replacement therapy, has the potential to compromise the integrity of the competition and must be disallowed.

With the health, safety and welfare of the athletes, and the integrity of our sport as top priorities, CrossFit Inc. has adopted the following Drug Testing Policy to ensure the validity of the results achieved in competition. This policy shall be administered under the authority of CrossFit Inc. CrossFit Inc. reserves the right to make changes to this policy at any time as needed, and this policy should not be construed as creating a contract between the athlete and CrossFit.

2. ATHLETE CONSENT

As a condition of participation in any CrossFit Games competition, each competing athlete agrees to undergo drug testing in accordance with this policy. Any athletes invited to participate at a CrossFit Games event must also agree to undergo drug testing. Refusal to consent to, or comply with, the requirements of this policy prohibits an athlete from participating in a CrossFit Games event.

All athletes registered in any CrossFit Games competition are subject to drug testing at any time during the year, including directed, unannounced out-of-competition testing, for any reason.

3. DRUG TESTING

The CrossFit Games Drug Testing Policy aims to prevent the use of prohibited substances through rigorous testing. CrossFit Inc. uses a combination of directed and random in-competition and out-of-competition drug testing to deter athletes from the use of prohibited performance-enhancing substances, and to detect the use of these substances by athletes.

Drug tests may include, but are not limited to, analysis for any of the banned substance classes listed on the Banned Substance Classes List (see **APPENDIX A**), including, but not limited to, stimulants, anabolic agents, diuretics (and other masking agents), and peptide hormones (and their analogues).

Specimen analysis requires collecting urine or blood samples and securely shipping these samples to the laboratory while maintaining the confidentiality of the athlete and integrity of the sample. **ALL COLLECTIONS AND/OR TESTING UNDER THIS POLICY SHALL BE OBSERVED COLLECTIONS.**

General guidelines for urine sample collection are available in **APPENDIX B**.

Note: The possession and/or use of banned substances may be determined by means other than urinalysis or blood sample. For example, when an individual is found to be in possession and/or using such substances, the individual may be subject to the same sanctions that would be followed in the case of a positive test.

4. CHAMPIONSHIPS/OUT-OF-COMPETITION DRUG TESTING

CrossFit Inc. is committed to providing a comprehensive drug testing program, including both championships and out-of-competition testing.

- **Championships Drug Testing:** may occur on site at ANY CrossFit Games competition. The selection of athletes to be drug tested may be based on directed selection, random selection or position of finish.
- **Out-of-Competition Testing:** All registered athletes, having electronically signed the drug testing consent form as part of the registration process, are subject to unannounced, directed or random testing outside of competition, 365 days a year, at any time and any place. Directed selections will be made solely at the discretion of CrossFit Inc. Random selections may be generated electronically from a pool of athletes selected by CrossFit Inc.

5. REGISTERED ATHLETE TESTING POOL (OUT-OF-COMPETITION DRUG TESTING)

CrossFit Inc. will select athletes to be included in CrossFit's **Registered Athlete Testing Pool** or "Testing Pool." As long as an athlete is included in the Testing Pool, the athlete must furnish accurate and up-to-date contact and whereabouts information for the purpose of facilitating drug tests (see **Section 6: Removal From Testing Pool/Retirement** and **Section 6A: Removal From Testing Pool/Watch List** for more information).



CrossFit Inc. will provide email notification to athletes when they have been selected for the Registered Athlete Testing Pool and will furnish the athletes with a contact information form at that time. A method for updating this form on a continuous basis will also be provided. All contact information collected for the purpose of administering drug tests will be kept strictly confidential.

Athletes included in the Testing Pool must submit complete and accurate contact and whereabouts information quarterly. Contact and whereabouts information is due no later than one day prior to the beginning of each quarter. Deadlines for submitting this information are:

- **Dec. 31** for the first quarter (beginning Jan. 1)
- **March 31** for the second quarter (beginning April 1)
- **June 30** for the third quarter (beginning July 1)
- **Sept. 30** for the fourth quarter (beginning Oct. 1)

Once the quarterly whereabouts information has been submitted, athletes must notify CrossFit Inc. promptly of any changes to their contact and whereabouts information by emailing updated information to drugtesting@crossfitgames.com.

Testing Pool athletes who plan to travel away from the address(es) listed on their contact information form, thereby making it impossible for them to meet a collection agent at the listed address(es) within **12 hours** of the **initial** contact from the collection agent, must update their contact information prior to traveling.

If athletes fail to provide and/or update their contact or whereabouts information, or provide incorrect or false information, and this results in the inability of the collection agent to contact the athletes or to administer a drug test within an acceptable amount of time, those athletes may be charged with violating the Drug Testing Policy and be subject to sanctions.

It is the sole responsibility of athletes to ensure that their contact and whereabouts information is accurate and up to date. Failure to do so may lead to sanctions.

6. REMOVAL FROM TESTING POOL/RETIREMENT

CrossFit Inc. retains the right to test athletes in the Registered Athlete Testing Pool at any time and any location. Once athletes have been included in the Testing Pool, athletes will remain in the Testing Pool and subject to testing until the athletes receive written notification from CrossFit Inc. that they have been removed from the Testing Pool.

Retiring athletes must first inform CrossFit Inc. in writing of their intent to retire. Until CrossFit Inc. has sent the athlete acknowledgment of the receipt of this written notification, the athlete must continue to provide contact and whereabouts information and must submit to drug testing. Failure to fulfill these requirements will be seen as a violation of the Drug Testing Policy and may result in sanctions. CrossFit Inc. will not suspend the prosecution of a Drug Testing Policy violation due to an athlete's impending retirement.

If athletes previously included in the Testing Pool wish to come out of formal retirement and return to full competition privileges, they must notify CrossFit in writing of their intent to compete AT LEAST six months before participating in any CrossFit Games competition. The athletes will immediately be required to furnish current contact and whereabouts information. The athletes also will be subject to drug testing immediately and at any time.

6A. REMOVAL FROM TESTING POOL/WATCH LIST

Any Testing Pool athletes who formally retire from competition or notify CrossFit Inc. that they are taking a leave of absence from competition may, at CrossFit Inc.'s sole discretion, be included on the **CrossFit Games Drug Testing Policy Watch List**. Watch List athletes will not be required to furnish contact and whereabouts information but remain eligible for drug testing at any time. As long as an athlete included on the Watch List does not provide contact and whereabouts information, that athlete is not eligible for advancement or to claim prizes in any CrossFit Games competition. Athletes will be notified by email of their inclusion on, and removal from, the Watch List. Any Watch List athletes who wish to return to full competition privileges must notify CrossFit Inc. in writing of their intent to compete AT LEAST six months before participating in any CrossFit Games competition. The athletes will then re-enter the Testing Pool and immediately be required to furnish current contact and whereabouts information.

7. TESTING POOL REQUIREMENTS FOLLOWING A SANCTION

Any Testing Pool athlete serving a sanction imposed by CrossFit Inc. will remain in the Testing Pool and subject to drug testing. The athlete will be required to furnish contact and whereabouts information in compliance with this policy and will be subject to drug testing at any time. Failure by an athlete to comply with all aspects of the Drug Testing Policy may result in further sanctions.



Any athlete who is sanctioned due to a violation of the Drug Testing Policy will be included in the Registered Athlete Testing Pool. The athlete will continue to be subject to drug testing at any time and must provide contact and whereabouts information. Failure to provide contact and whereabouts information as required may result in further sanctions.

8. DRUG TEST NOTIFICATION AND ADMINISTRATION

Any athlete selected for drug testing on site at a CrossFit Games competition will be notified of this test by Athlete Control personnel. Athlete Control personnel will escort the athlete to the drug testing station, where a contracted collection agent from Drug Free Sport will administer the drug test.

Any athlete selected for out-of-competition drug testing will be notified by the contracted collection agent from Drug Free Sport. Notification may occur through a phone call, email or text message to set up a face-to-face meeting between the athlete and collection agent for the purpose of conducting the drug test.

If an athlete fails to comply with the sample-collection procedure, or refuses or fails to provide a sample, the athlete will be charged with refusing to provide a sample and subject to the same sanctions applied for a positive drug test.

If a collection agent is unable to contact an athlete or the athlete fails to meet with the collection agent within an acceptable amount of time to conduct the drug test, the athlete will be held responsible for the missed test and may be sanctioned.

See **APPENDIX B** for general urine sample collection protocol.

9. SPECIMEN ANALYSIS

Collected urine and/or blood samples will be sent to a World Anti-Doping Agency-approved laboratory for analysis. Samples will be tested in accordance with WADA guidelines to determine if banned drugs or substances are present. Appropriate sanctions will apply for positive drug test results.

If the laboratory reports a specimen as substituted, manipulated or adulterated in any way, the athlete will be charged with refusing to submit to a drug test. The athlete will be subject to the same sanctions applied to a positive drug test.

10. REPORTING RESULTS

Drug test results will be reported to CrossFit by Drug Free Sport. CrossFit Inc. will notify athletes of a positive test result by email.

CrossFit Inc., at its sole discretion, will publicly announce violations of the CrossFit Games Drug Testing Policy once the appeals process is over and a final decision has been reached. These announcements will include the athlete's name, whether the test was in-competition or out-of-competition, the date of sample collection, the infraction and the sanction imposed.

11. DRUG TESTING POLICY VIOLATIONS

Violations of the Drug Testing Policy for which an athlete may be sanctioned include, but are not limited to:

- Positive drug test result: indicates the presence of a prohibited substance, its metabolites or markers in an athlete's blood or urine sample.
- Substitution, manipulation or adulteration of a sample as determined by the collection agent or laboratory.
- Use, attempted use or possession by an athlete of a prohibited substance.
- Use or attempted use by an athlete of a prohibited method.
- Evading, refusing or failing to submit to a drug test.
- Whereabouts violations:
 - athlete fails to submit required quarterly whereabouts information to CrossFit by the specified deadline.
 - athlete fails to update whereabouts information as required.
 - athlete provides whereabouts information that is incomplete or inaccurate, which does not allow for athlete to be reasonably located for the purpose of drug testing.
 - athlete misses test for any reason.
- Trafficking or attempted trafficking of any prohibited substance or prohibited method.



12. ENFORCEMENT/SANCTIONS

Athletes who violate the Drug Testing Policy are subject to sanctions. These sanctions may be applied to the entire team if a team athlete violates the Drug Testing Policy. Sanctions will be imposed at the sole discretion of CrossFit Inc. based on the circumstances present in each case. Possible sanctions include, but are not limited to, any combination of the following:

- Disqualification from the competition and loss of results.
- Loss of results from previous competitions.
- Forfeit or required return of any prizes, awards or money.
- Suspension from participating in future CrossFit Games events. The length of this suspension will be determined by CrossFit Inc. on a case-by-case basis and may include a lifetime ban from all CrossFit Games events.
- Public disclosure.

NOTE: CrossFit Inc. may recognize drug policy violations, including positive drug tests, reported by other anti-doping organizations (e.g., US-ADA) from in-competition or out-of-competition testing performed by these agencies on behalf of other sports-governing bodies. Upon learning of a positive test result or other violation, CrossFit Inc. may provisionally suspend an athlete awaiting a final decision by the testing agency or sports-governing body. Once a final decision in the case has been announced by the testing agency or sports-governing body, CrossFit Inc. will, in each case, determine its own sanction for the athlete involved.

13. APPEALS PROCESS

Athletes who commit a violation of the Drug Testing Policy will have the right to state their case prior to any sanctions being imposed. Within 72 hours of being notified of their violation, an athlete must provide written notice of their intent to submit a written petition of appeal concerning the violation. Athletes' requests to have their B sample tested and for any pertinent documents must be made within this initial 72-hour period and not at a later date. The available documents include a copy of the test results and a "documentation package" that includes all documents related to the acquisition of the sample and its processing. The documentation package will be provided at the athlete's expense.

Thereafter, from the time of receipt of any materials provided by CrossFit Inc., the athletes have 10 business days to submit their written petition of appeal explaining why they are not in violation of the Drug Testing Policy.

Following a review of the athlete's petition of appeal, CrossFit Inc. will respond in a timely manner to provide a written response of its decision, including supporting reasons, either to deny or grant the appeal. If, after this investigation, the athlete is found to be in violation of the Drug Testing Policy, CrossFit Inc. will proceed with applying any appropriate sanctions.

In extraordinary cases, the athlete may request a personal hearing, and it will be at CrossFit Inc.'s sole discretion to grant or deny such a request. The athlete may have an advocate or other representative present, if the athlete so desires, at any such hearing. However, CrossFit Inc. will only consider and review statements made by the athlete, not those made by a coach or representative. CrossFit Inc. personnel present will confer and decide upon the appeal. Any decision made at such a hearing by CrossFit Inc. regarding the violation and any sanction(s) to be imposed shall be final.

14. LEADERBOARD DISPLAY

Should an athlete violate the Drug Policy during live competition, the athlete's scores from the competition will be removed from the Leaderboard and his or her rankings will display a DQ. Any athletes ranked below the disqualified athlete will move up in the overall rankings. CrossFit Inc. will not re-sort or re-calculate the rankings as if the athlete never competed. All event scores and event rankings will remain the same.

15. EDUCATION

CrossFit Inc. recognizes its responsibility to provide performance-enhancing drug and supplement education, and to promote fitness and lifestyle choices consistent with CrossFit Inc.'s models for fitness and health. Participants who are educated about prohibited substances in sport are more likely to make informed and intelligent decisions concerning the use of these substances. CrossFit Inc. will, through publicly available media, continue to provide athletes, coaches and other members of the community with current and accurate information about prohibited substances and the inherent risks associated with their use. Appropriate educational materials, including this policy and a list of banned substance classes (see **APPENDIX A**), will be made available to participants.



16. DIETARY SUPPLEMENTS

CrossFit Inc. highly encourages athletes to research any dietary supplements or ergogenic aids prior to use. Many dietary supplements or ergogenic aids contain banned substances. Often, the labeling of dietary supplements is not accurate and is misleading. Terms such as “healthy” or “all natural” do not mean dietary supplements are free of banned substances or are safe to take. In an investigation prompted by the International Olympic Committee in 2001,¹ an analysis of 634 supplements worldwide found nearly 15 percent of these supplements to contain substances that would cause a positive drug test, but these banned substances were not listed on the product label. In the United States, the percentage of supplements that were tainted with banned substances reached almost 19 percent. Thus, using dietary supplements may cause positive drug tests.

ATHLETES ARE SOLELY RESPONSIBLE FOR WHAT THEY PUT ON OR INTO THEIR BODIES. Therefore, athletes must act responsibly. Athletes should seek out substances that are labeled as safe for athletic use in accordance with standards from a legitimate agency, such as the Banned Substances Control Group (BSCG), HFL Sports Science, NSF International (which certifies supplements for Major League Baseball and the National Football League), ConsumerLab and the National Products Association (This is not an endorsement of any of these organizations but simply an educational statement for athletes to examine). Athletes should also be cautious when taking any substance that says that it is anabolic or muscle-building, or that it will improve recovery, add intensity to a workout (“pre-workout” supplements), or otherwise enhance performance. Supplements offering these claims have been, historically, more likely to cause failed drug tests among CrossFit Games competitors.

17. TRANSGENDER POLICY:

Transgender athletes are required to comply with the requirements of CrossFit’s Transgender Policy as set forth in Section 6 of the CrossFit Games Rulebook. Any transgender athlete planning to use a banned substance as part of a medically supervised gender transition must obtain a Therapeutic Use Exemption under Section 18 of this policy before registering for or any part of the CrossFit Games.

18. THERAPEUTIC USE EXEMPTION

CrossFit Inc. recognizes that some banned substances are used for legitimate medical purposes. In rare cases, CrossFit Inc. permits a **Therapeutic Use Exemption (TUE)** to be granted for those athletes with a documented medical history demonstrating the need for the regular use of such a drug. CrossFit Inc. adheres to the standards set by the World Anti-Doping Agency (WADA) and will only grant a TUE in strict accordance with all of the following criteria:²

- The athlete would experience a significant impairment to health if the prohibited substance were to be withheld in the course of treating an acute or chronic medical condition.
- The therapeutic use of the banned substance would produce no additional enhancement of performance other than that which might be anticipated by a return to a state of normal health following the treatment of a legitimate medical condition. (**Note:** The use of a banned substance to increase “low-normal” levels of any endogenous hormone is not considered an acceptable therapeutic intervention.)
- There is no reasonable therapeutic alternative to the use of the otherwise banned substance.
- The necessity for the use of the otherwise banned substance cannot be a consequence, wholly or in part, of the prior use without a TUE of a substance that was banned at the time of use.

CrossFit requires all athletes seeking to use a banned substance for medical treatment to submit a **Therapeutic Use Exemption form**. Completion of a TUE Form is required documentation and not an official approval to use such banned substances. However, failure to submit a TUE Form requesting that CrossFit allow the use of a banned substance for medical treatment may disqualify an athlete or team from competition.

Transgender athletes planning to use a banned substance are required to submit a TUE form. A TUE form needs to include a report by a health professional providing care for transgender persons and detail the medical history, including any previous partially or fully reversible physical treatment. This report should be complemented by an endocrinologist’s report on initialization of hormone therapy and a surgical report where applicable. Prior to treatment, a full general medical assessment needs to be completed to assess the individual risk associated with the different therapeutic options.³ CrossFit Inc. will evaluate the TUE applications submitted by transgender athletes under the most current version of the WADA “TUEC Guidelines Medical Information to Support the Decisions of TUE Committees – Transgender Athletes”.

Note: In the event of an acute incident such as a severe allergic reaction (anaphylaxis), or an acute asthma or coughing attack where a banned substance is required for the immediate and short-term treatment of the athlete, a retrospective/emergency TUE will be required only for in-competition periods and for the banned substance in question (e.g., glucocorticosteroid or epinephrine). These incidents are rare and will be dealt with on a case-by-case basis.

Note: Except in the case of transgender athletes granted a TUE under the WADA guidelines, a Therapeutic Use Exemption for Hormone Replacement Therapy for using anabolic substances will NOT be granted under any circumstances for either men or women. Therefore, any athlete who tests positive for any anabolic agents (e.g., testosterone), even if these anabolic agents are taken as part of medically supervised hormone

¹ Dr. Wilhelm Schänzer, “Analysis of Non-Hormonal Nutritional Supplements for Anabolic-Androgenic Steroids - An International Study: An Investigation of the IOC Accredited Doping Laboratory Cologne, Germany” (Cologne, Germany: German Sport University Cologne, 2001), 1-2.

² “World Anti-Doping Programme: Therapeutic Use Exemption Guidelines.” (World Anti-Doping Agency, Jan. 2012), 12-13.

³ Adapted from WADA’s “TUEC Guidelines. Medical Information to Support the Decisions of TUE Committees. Transgender Athletes” Oct. 2017.



2019 DRUG TESTING PROGRAM

replacement therapy, will be disqualified from competition and subject to the appropriate sanctions as imposed by CrossFit Inc.

All TUE forms, along with the required supporting documentation, must be turned in to CrossFit at support@crossfitgames.com. Incomplete TUE requests will not be reviewed (see **APPENDIX C** for TUE documentation requirements). Each completed TUE application will be reviewed and a final determination as to whether the exempted use is allowed will be communicated to the athlete by email. Decisions on whether to grant the Therapeutic Use Exemption may take 30 days or longer. Athletes must submit their TUE form with sufficient time for a decision to be made in their case **before they participate in the Online Qualifier or accept the invitation to participate in the CrossFit Games**. Any athletes who test positive for a banned substance and have not been granted a Therapeutic Use Exemption for that substance, even if they have submitted a TUE form that is currently under review, may be charged with a positive drug test and subject to sanctions.

TUE forms expire at the end of each year for which the exemption was granted. Therefore, a new TUE form must be submitted each year even if a TUE was previously granted, and even if the diagnosis, condition, drugs used and treatment remain unchanged. Unless a current and valid TUE has been granted, an athlete testing positive for a banned substance, even if the banned substance is administered in the treatment of a medical condition, will be subject to the sanctions outlined in this policy for a failed drug test.

TUE submissions will be handled with the strictest confidentiality by CrossFit Inc.



APPENDIX A: 2019 CROSSFIT BANNED SUBSTANCE CLASSES

CROSSFIT INC. BANS THE FOLLOWING CLASSES OF DRUGS AT ALL TIMES:

- Anabolic Agents
- Street Drugs
- Diuretics and Other Masking Agents
- Peptide Hormones and Analogues
- Hormone and Metabolic Modulators
- Beta-2 Agonists (permitted with prescription and TUE, and through inhalation only)

SOME EXAMPLES OF BANNED SUBSTANCES IN EACH DRUG CLASS:

- **Anabolic Agents** (sometimes listed as a chemical formula, such as 3,6,17-androstenetrione): anabolic androgenic steroids;
 - Exogenous Anabolic Androgenic Steroids:
 - 1-Androstenediol (5 α -androst-1-ene-3 β ,17 β -diol); 1-Androstenedione (5 α -androst-1-ene-3,17-dione); 1-Androsterone (3 α -hydroxy-5 α -androst-1-ene-17-one); 1-Testosterone (17 β -hydroxy-5 α -androst-1-en-3-one); Bolasterone; Calusterone; Clostebol; Danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17 α -ol); Dehydrochloromethyltestosterone (4-chloro-17 β -hydroxy-17 α -methylandrosta-1,4-dien-3-one); Desoxymethyltestosterone (17 α -methyl-5 α -androst-2-en-17 β -ol and 17 α -methyl-5 α -androst-3-en-17 β -ol); Drostanolone; Ethylestrenol (19-norpregna-4-en-17 α -ol); Fluoxymesterone; Formebolone; Furazabol (17 α -methyl [1,2,5]oxadiazolo[3',4':2,3]-5 α androstan-17 β -ol); Gestrinone; Mestanolone; Mesterolone; Metandienone (17 β -hydroxy-17 α -methylandrosta-1,4-dien-3-one); Metenolone; Methandriol; Methasterone (17 β -hydroxy-2 α ,17 α -dimethyl-5 α androstan-3-one); Methyldienolone (17 β -hydroxy-17 α -methylestra-4,9-dien-3-one); Methyl-1-testosterone (17 β -hydroxy-17 α -methyl-5 α androst-1-en-3-one); Methylnortestosterone (17 β -hydroxy-17 α -methylestr-4-en-3-one); Methyltestosterone; Metribolone (methyltrienolone, 17 β -hydroxy-17 α methylestra-4,9,11-trien-3-one); Mibolerone; Norboletone; Norclostebol; Norethandrolone; Oxabolone; Oxandrolone; Oxymesterone; Oxymetholone; Prostanazol (17 β -[(tetrahydropyran-2-yl)oxy]-1'Hpyrazolo[3,4:2,3]-5 α -androstane); Quinbolone; Stanazolol; Stenbolone; Tetrahydrogestrinone (17-hydroxy-18 α -homo-19-nor-17 α pregna-4,9,11-trien-3-one); Trenbolone (17 β -hydroxyestr-4,9,11-trien-3-one); and other substances with a similar chemical structure or similar biological effect(s).
 - Endogenous Anabolic Androgenic Steroids and their Metabolites and isomers wne administered exogenously
 - 4-Androstenediol (androst-4-ene-3 β ,17 β -diol); 4-Hydroxytestosterone (4,17 β -dihydroxyandrost-4-en-3-one); 5-Androstenedione (androst-5-ene-3,17-dione); 7 α -hydroxy-DHEA; 7 β -hydroxy-DHEA; 7-keto-DHEA; 19-Norandrostenediol (estr-4-ene-3,17-diol); 19-Norandrostenedione (estr-4-ene-3,17-dione); Androstanolone (5 α -dihydrotestosterone, 17 β -hydroxy-5 α androstan-3-one); Androstenediol (androst-5-ene-3 β ,17 β -diol); Androstenedione (androst-4-ene-3,17-dione); Boldenone; Boldione (androsta-1,4-diene-3,17-dione); Epiandrosterone (3 β -hydroxy-5 α -androstan-17-one); Epi-dihydrotestosterone (17 β -hydroxy-5 β -androstan-3-one); Epitestosterone; Nandrolone (19-nortestosterone); Prasterone (dehydroepiandrosterone, DHEA, 3 β -hydroxyandrost-5-en-17-one); Testosterone.
- **Street Drugs:** For example: heroin; cocaine
- **Diuretics and Other Masking Agents:**
 - Including but not limited to:
 - Desmopressin; probenecid; plasma expanders, e.g. intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol. • Acetazolamide; amiloride; bumetanide; canrenone; chlortalidone; etacrynic acid; furosemide; indapamide; metolazone; spironolactone; thiazides, e.g. bendroflumethiazide, chlorothiazide and hydrochlorothiazide; triamterene and vaptans, e.g. tolvaptan.
 - Except:
 - Drospirenone; pamabrom; and ophthalmic use of carbonic anhydrase inhibitors (e.g. dorzolamide, brinzolamide); • Local administration of felypressin in dental anaesthesia.
 - The detection in an Athlete's Sample at all times or In-Competition, as applicable, of any quantity of the following substances subject to threshold limits: formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine, in conjunction with a diuretic or masking agent, will be considered as an Adverse Analytical Finding (AAF) unless the Athlete has an approved Therapeutic Use Exemption (TUE) for that substance in addition to the one granted for the diuretic or masking agent.
- **Peptide Hormones and Analogues:**
 - Erythropoietins (EPO) and agents affecting erythropoiesis, including, but not limited to:

- Erythropoietin-Receptor Agonists, e.g. Darbepoetins (dEPO); Erythropoietins (EPO); EPO based constructs [e.g. EPO-Fc, methoxy polyethylene glycol-epoetin beta (CERA)]; EPO-mimetic agents and their constructs (e.g. CNTO-530, peginesatide).
 - Hypoxia-inducible factor (HIF) activating agents, e.g. Argon; Cobalt; Daprodustat (GSK1278863); Molidustat (BAY 85-3934); Roxadustat (FG-4592); Vadadustat (AKB-6548); Xenon.
 - GATA inhibitors, e.g. K-11706.
 - TGF-beta (TGF- β) inhibitors, e.g. Luspatercept; Sotatercept.
 - Innate repair receptor agonists, e.g. Asialo EPO; Carbamylated EPO (CEPO).
 - Peptide Hormones and their Releasing Factors,
 - Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) and their releasing factors in males, e.g. Buserelin, deslorelin, gonadorelin, goserelin, leuprorelin, nafarelin and triptorelin;
 - Corticotrophins and their releasing factors, e.g. Corticorelin;
 - Growth Hormone (GH), its fragments and releasing factors, including, but not limited to: Growth Hormone fragments, e.g. AOD-9604 and hGH 176-191; Growth Hormone Releasing Hormone (GHRH) and its analogues, e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin; Growth Hormone Secretagogues (GHS), e.g. lenomorelin (ghrelin) and its mimetics, e.g. anamorelin, ipamorelin, macimorelin and tabimorelin; GH-Releasing Peptides (GHRPs), e.g. alexamorelin, GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5, GHRP-6, and examorelin (hexarelin).
 - Growth Factors and Growth Factor Modulators, including, but not limited to: Fibroblast Growth Factors (FGFs); Hepatocyte Growth Factor (HGF); Insulin-like Growth Factor-1 (IGF-1) and its analogues; Mechano Growth Factors (MGFs); Platelet-Derived Growth Factor (PDGF); Thymosin- β 4 and its derivatives e.g. TB-500; Vascular-Endothelial Growth Factor (VEGF);
 - and other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/ degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching
- **Hormone and Metabolic Modulators:**
 - Aromatase inhibitors including, but not limited to:
 - 2-Androstenol (5 α -androst-2-en-17-ol); 2-Androstenone (5 α -androst-2-en-17-one); 3-Androstenol (5 α -androst-3-en-17-ol); 3-Androstenone (5 α -androst-3-en-17-one); 4-Androstene-3,6,17 trione (6-oxo); Aminoglutethimide; Anastrozole; Androsta-1,4,6-triene-3,17-dione (androstatienedione); Androsta-3,5-diene-7,17-dione (arimistane); Exemestane; Formestane; Letrozole; Testolactone.
 - Selective estrogen receptor modulators (SERMs) including, but not limited to:
 - Raloxifene; Tamoxifen; Toremifene.
 - Other anti-estrogenic substances including, but not limited to:
 - Clomifene; Cyclofenil; Fulvestrant.
 - Agents preventing activin receptor IIB activation including, but not limited, to:
 - Activin A-neutralizing antibodies; Activin receptor IIB competitors such as: Decoy activin receptors (e.g. ACE-031); Anti-activin receptor IIB antibodies (e.g. bimagrumab); Myostatin inhibitors such as: Agents reducing or ablating myostatin expression; Myostatin-binding proteins (e.g. follistatin, myostatin propeptide); Myostatin-neutralizing antibodies (e.g. domagrozumab, landogrozumab, stamulumab).
 - Metabolic modulators:
 - Activators of the AMP-activated protein kinase (AMPK), e.g. AICAR, SR9009; and Peroxisome Proliferator Activated Receptor δ (PPAR δ) agonists, e.g. 2-(2-methyl-4-((4-methyl-2-(4- δ (trifluoromethyl) phenyl)thiazol-5-yl)methylthio)phenoxy) acetic acid (GW1516, GW501516);
 - Insulins and insulin-mimetics;
 - Meldonium;
 - Trimetazidine
- **Beta-2 Agonists:**
 - Fenoterol; Formoterol; Higenamine; Indacaterol; Olodaterol; Procaterol; Reproterol; Salbutamol; Salmeterol; Terbutaline; Tretoquinol (trimetoquinol); Tulobuterol; Vilanterol
 - Except:
 - Inhaled salbutamol: maximum 1600 micrograms over 24 hours in divided doses not to exceed 800 micrograms over 12 hours



- starting from any dose;
- Inhaled formoterol: maximum delivered dose of 54 micrograms over 24 hours;
- Inhaled salmeterol: maximum 200 micrograms over 24 hours.
- o The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is not consistent with therapeutic use of the substance and will be considered as an Adverse Analytical Finding (AAF) unless the Athlete proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of a therapeutic dose (by inhalation) up to the maximum dose indicated above

CROSSFIT INC. BANS THE FOLLOWING CLASSES OF DRUGS IN COMPETITION:

- Stimulants: All stimulants, including all optical isomers, e.g., d- and l- where relevant, are prohibited
- Narcotics
- Cannabinoids
- Glucocorticoids

SOME EXAMPLES OF BANNED SUBSTANCES IN EACH DRUG CLASS:

- Stimulants:
 - o Non-Specified Stimulants:
 - Adrafinil; Amfepramone; Amphetamine; Amfetaminil; Amiphenazole; Benfluorex; Benzylpiperazine; Bromantan; Clobenzorex; Cocaine; Cropropamide; Crotetamide; Fencamine; Fenetylline; Fenfluramine; Fenproporex; Fonturacetam [4-phenylpiracetam (carphedon)]; Furfenorex; Lisdexamphetamine; Mefenorex; Mephentermine; Mesocarb; Metamphetamine(d-); p-methylamphetamine; Modafinil; Norfenfluramine; Phendimetrazine; Phentermine; Prenylamine; Prolintane
 - o Specified Stimulants:
 - 3-Methylhexan-2-amine (1,2-dimethylpentylamine); 4-Methylhexan-2-amine (methylhexaneamine); 4-Methylpentan-2-amine (1,3-dimethylbutylamine); 5-Methylhexan-2-amine (1,4-dimethylpentylamine); Benzfetamine; Cathine**; Cathinone and its analogues, e.g. mephedrone, methedrone, and α - pyrrolidinovalerophenone; Dimetamphetamine; Ephedrine***; Epinephrine**** (adrenaline); Etamivan; Etilamphetamine; Etilefrine; Famprofazone; Fenbutrazate; Fencamfamin; Heptaminol; Hydroxyamphetamine (parahydroxyamphetamine); Isometheptene; Levmetamphetamine; Meclofenoxate; Methylenedioxyamphetamine; Methylephedrine***; Methylphenidate; Nikethamide; Norfenefrine; Octopamine; Oxilofrine (methylsynephrine); Pemoline; Pentetrazol; Phenethylamine and its derivatives; Phenmetrazine; Phenpromethamine; Propylhexedrine; Pseudoephedrine*****; Selegiline; Sibutramine; Strychnine; Tenamphetamine (methylenedioxyamphetamine); Tuaminoheptane; and other substances with a similar chemical structure or similar biological effect(s).

* Bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradrol, and synephrine: These substances are included in the 2019 Monitoring Program, and are not considered Prohibited Substances.

** Cathine: Prohibited when its concentration in urine is greater than 5 micrograms per milliliter.

*** Ephedrine and methylephedrine: Prohibited when the concentration of either in urine is greater than 10 micrograms per milliliter.

**** Epinephrine (adrenaline): Not prohibited in local administration, e.g. nasal, ophthalmologic, or co-administration with local anaesthetic agents.

***** Pseudoephedrine: Prohibited when its concentration in urine is greater than 150 micrograms per milliliter

- Narcotics:
 - o Buprenorphine; Dextromoramide; Diamorphine (heroin); Fentanyl and its derivatives; Hydromorphone; Methadone; Morphine; Nicomorphine; Oxycodone; Oxymorphone; Pentazocine; Pethidine
- Cannabinoids:
 - o Natural cannabinoids; cannabis, hashish and marijuana; synthetic cannabinoids e.g. Δ 9-tetrahydrocannabinol (THC) and other cannabimimetics. (Exceptions: cannabidiol)
- Glucocorticoids:
 - o Betamethasone; Budesonide; Cortisone; Deflazacort; Dexamethasone; Fluticasone; Hydrocortisone; Methylprednisolone; Prednisolone; Prednisone; Triamcinolone.



PROHIBITED METHODS AND PROCEDURES SUBJECT TO RESTRICTIONS:

- Manipulation of blood and blood components: The following are prohibited:
 - The administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood, or red blood cell products of any origin into the circulatory system.
 - Artificially enhancing the uptake, transport or delivery of oxygen. Including, but not limited to: Perfluorochemicals; efaproxiral (RSR13) and modified haemoglobin products, e.g. haemoglobin-based blood substitutes and microencapsulated haemoglobin products, excluding supplemental oxygen by inhalation
 - Any form of intravascular manipulation of the blood or blood components by physical or chemical means.
- Intravenous infusions
 - Intravenous infusions and/or injections of more than a total of 100 mL per 12 hour period except for those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations.
- Local anesthetics (under some conditions)
- Manipulation of urine samples
 - Tampering, or attempting to tamper, to alter the integrity and validity of samples collected during doping control. Including, but not limited to: Urine substitution and/or adulteration, e.g. proteases.
- Caffeine if concentrations in urine exceed 15 micrograms/ml
- Gene doping: The following, with the potential to enhance sport performance, are prohibited:
 - The use of polymers of nucleic acids or nucleic acid analogues.
 - The use of gene editing agents designed to alter genome sequences and/or the transcriptional, post-transcriptional or epigenetic regulation of gene expression.
 - The use of normal or genetically modified cells.

There is no complete list of banned drugs. New banned substance classes emerge constantly. The most current and complete list is available at www.wada-ama.org/en/content/what-is-prohibited. In addition, any substance that is chemically related to the class of banned drugs is also banned. Athletes shall be held accountable for all drugs within the banned drug class, regardless of whether or not they have been specifically identified as banned. For example, designer drugs chemically related to banned substances are banned even if a name has yet to be created for them.

NUTRITIONAL/DIETARY SUPPLEMENTS WARNING:

Before consuming any nutritional/dietary supplement, research the product and consult a physician or pharmacist. Dietary supplements are not well-regulated and may cause a positive drug test result. Athletes have tested positive and received sanctions for using tainted dietary supplements, even when labels claim the product is safe and compliant. Many dietary supplements are contaminated with unlisted, banned substances.

Any dietary supplement is taken at your own risk. It is your responsibility to know what you are ingesting. Consult a pharmacist or doctor before using any supplement. You are responsible for what you put into your body. **BE RESPONSIBLE.**



APPENDIX B: CROSSFIT URINE TESTING PROCEDURES - (IN-COMPETITION)

Drug testing is certainly not the most glamorous aspect of an athlete's life, but it is essential to help ensure a fair and clean competition. The information in this appendix provides an overview of CrossFit's in-competition urine sample collection process:

1. Upon entering the collection station, the athlete will provide photo identification and/or a client representative/site coordinator will identify the athlete to the collector.
2. The athlete will select a sealed collection vessel from a supply of vessels and will record his/her initials on the collection vessel's lid.
3. A collector, serving as validator, will monitor the furnishing of the specimen by direct frontal observation in order to assure the integrity of the specimen.
4. Validators who are members of the official drug testing crew and are of the same gender as the athlete must observe the voiding process. The procedure does not allow for validators to stand outside the toilet area or outside the restroom. The athlete must urinate in full view of the validator (i.e., the validator must observe the flow of urine). The validator may request that the athlete raise his/her shirt high enough to observe the midsection area in order to completely rule out any attempt to manipulate or substitute a sample.
5. The athlete may not carry any item other than his/her vessel into the restroom when providing a specimen. Any problem or concern should be brought to the attention of the collection crew chief or CrossFit representative for documentation. The athlete will rinse and dry hands, with water only, prior to urination.
6. Once a specimen is provided, the athlete is responsible for keeping the collection vessel closed and under his/her control.
7. Fluids and food given to athletes who have difficulty voiding must be from sealed containers (approved by the collector) that are opened and consumed in the station. These items must be caffeine- and alcohol-free, and free of any other banned substances.
8. If the specimen is incomplete, the athlete must remain in the collection station until the sample is completed. During this period, the athlete is responsible for keeping the collection vessel closed and under his/her control. If the specimen is incomplete and the athlete must leave the collection station for a reason approved by the collector, the specimen may be discarded. Upon return to the collection station, the athlete may have to begin the collection procedure again.
9. Once an adequate volume of the specimen is provided, the collector who monitored the furnishing of the specimen by observation will sign that the specimen was directly validated. Then, based upon the urine testing process of the National Center for Drug Free Sport, a collector will measure the specific gravity of the sample in the presence of the athlete.
10. If the specific gravity of the urine is outside the acceptable ranges, the specimen will be discarded and the athlete must remain in the collection station until another specimen is provided.
11. If the sample's specific gravity is within the required range, the specimen will be processed and sent to the laboratory.
12. Once a specimen has been provided that meets the on-site parameters, the athlete will select a specimen collection kit from a supply of kits. The collector will review the electronic Chain of Custody Form with the athlete as this form is filled out.
13. The collector, in the presence of the athlete, will pour some of the specimen into the A vial and the remaining amount into the B vial.
14. The collector will place the cap on each vial in the presence of the athlete. The collector will then seal each vial in the required manner under the observation of the athlete.
15. All sealed specimens will be secured in a shipping case. The collector will prepare the case for shipping to the WADA-accredited laboratory.
16. The athlete and collector will sign an electronic document certifying procedures were followed as required. Any deviation from procedures shall be recorded. If an athlete deviates from the required procedure, another sample may have to be collected.
17. After the collection has been completed, the specimens will be forwarded to the laboratory and copies of all electronic forms saved and forwarded to the designated persons.
18. At this point, the specimens become the property of CrossFit Inc. and will be sent to the laboratory for analysis.
19. The laboratory will make final determination of specimen adequacy.
20. If the laboratory determines that an athlete's specimen is inadequate for analysis, at CrossFit's discretion, another specimen may be collected.
21. If an athlete is suspected of manipulating specimens (e.g., via dilution), CrossFit will have the authority to perform additional tests on the athlete or to sanction the athlete for refusing to provide a sample.
22. If at any time during the collection process the athlete does not comply with procedures or instructions, the collector will notify a CrossFit representative and the third-party administrator responsible for management of the drug testing program.



APPENDIX C: TUE APPLICATION REQUIREMENTS

This appendix outlines the documentation that must be attached to the completed Therapeutic Use Exemption (TUE) form in support of the application for a TUE:⁴

- Evidence of the diagnosis must be attached.
- Copies of the physician's original reports or letters must be attached. The application must include a comprehensive medical history and the results of all examinations, laboratory investigations and imaging studies relevant to the application. **Note:** Any additional relevant investigations, examinations or imaging studies requested by CrossFit's TUE committee before approval will be undertaken at the expense of the applicant.
- The application must include a statement by an appropriately qualified physician attesting to the necessity of the otherwise prohibited substance or prohibited method in the treatment of the athlete, and describing why an alternative, permitted medication cannot, or could not, be used in the treatment of this condition.
- For conditions that cannot be demonstrated, independent medical justification must be attached to the application.

The athlete must provide accurate and up-to-date contact information for CrossFit to use in delivering the decision as to whether the Therapeutic Use Exemption has been granted. The information provided in the TUE application must be up-to-date and exact, in terms of both content and form.

⁴ "World Anti-Doping Programme: Therapeutic Use Exemption Guidelines," (World Anti-Doping Agency, Jan. 2012), 14-15..